A Clinical Study of the HIV Drug CPT31 in Healthy Volunteers
Status:
Enrolling by invitation
Trial end date:
2021-04-01
Target enrollment:
Participant gender:
Summary
This first-in-human study will evaluate the safety, tolerability, immunogenicity, and
pharmacokinetics of the HIV entry inhibitor CPT31 (cholesterol-PIE12-2-trimer) in healthy
adults. This is a randomized, placebo-controlled, double-blind, single ascending dose study.
Phase:
Phase 1
Details
Lead Sponsor:
Navigen, Inc.
Collaborators:
Covance National Institute of Allergy and Infectious Diseases (NIAID)